Chronic inflammation increases the risk of several cancers, including gastric, colon, and
hepatic cancers. Conversely, tumors, similar to tissue injury, trigger an inflammatory …

While most studies of T lymphocytes have focused on T cells reactive to complexes of
peptide and major histocompatibility complex (MHC) proteins, many other types of T cells do …

Immunotherapies targeting conventional T cells have revolutionized systemic treatment for
many cancers, yet only a subset of patients benefit from these approaches. A better …

Most studies on the immunotherapeutic potential of T cells have focused on CD8 and CD4 T
cells that recognize peptide antigens (Ag) presented by polymorphic major histocompatibility …

The immune system responds to cancer in two main ways. First, there are prewired
responses involving myeloid cells, innate lymphocytes and innate-like adaptive lymphocytes …

Natural killer (NK) cells and natural killer T (NKT) cells are subsets of lymphocytes that share
some phenotypical and functional similarities. Both cell types can rapidly respond to the …

The immune system can identify and destroy nascent tumor cells in a process termed cancer
immunosurveillance, which functions as an important defense against cancer. Recently …

The stromal microenvironment of tumors, which is a mixture of hematopoietic and
mesenchymal cells, suppresses immune control of tumor growth. A stromal cell type that was …

Natural killer T (NKT) cells are a subset of CD1d-restricted T cells at the interface between
the innate and adaptive immune system. NKT cells can be subdivided into functional …

Many cancer immunotherapies developed in experimental animals have been tested in
clinical trials. Although some have shown modest clinical effects, most have not been …